These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31772945)

  • 1. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Wang J; Jin X; An P; Yu S; Mu Y
    J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
    Stonehouse A; Walsh B; Cuddihy R
    Diabetes Technol Ther; 2011 Oct; 13(10):1063-9. PubMed ID: 21732798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide extended-release; clinical trials, patient preference, and economic considerations.
    Doggrell SA
    Patient Prefer Adherence; 2013; 7():35-45. PubMed ID: 23341736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
    Divino V; DeKoven M; Hallinan S; Varol N; Wirta SB; Lee WC; Reaney M
    Diabetes Ther; 2014 Dec; 5(2):499-520. PubMed ID: 25366334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
    Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of exenatide as a diabetes therapeutic.
    Bhavsar S; Mudaliar S; Cherrington A
    Curr Diabetes Rev; 2013 Mar; 9(2):161-93. PubMed ID: 23256660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
    Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
    Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
    Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
    Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
    Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
    Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.
    Gorgojo-Martínez JJ; Gargallo-Fernández MA; Brito-Sanfiel M; Lisbona-Catalán A
    Int J Clin Pract; 2018 Mar; 72(3):e13055. PubMed ID: 29341370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.